Alto Neuroscience (Alto Neuroscience) Interest Income : $2.30 Mil (TTM As of Mar. 2024)

View and export this data going back to 2024. Start your Free Trial

What is Alto Neuroscience Interest Income?

Interest Income is the interest earned on cash temporarily held in savings accounts, certificates of deposits, or other investments. Alto Neuroscience's interest income for the three months ended in Mar. 2024 was $1.56 Mil. Its interest income for the trailing twelve months (TTM) ended in Mar. 2024 was $2.30 Mil.

Alto Neuroscience Interest Income Historical Data

The historical data trend for Alto Neuroscience's Interest Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Alto Neuroscience Interest Income Chart

Alto Neuroscience Annual Data

Trend

Dec21

Dec22

Dec23

Interest Income

0.11

2.35

Alto Neuroscience Quarterly Data
	Dec21	Sep22	Dec22	Mar23	Sep23	Dec23	Mar24
Interest Income	Get a 7-Day Free Trial			0.11	0.23	-	0.74	1.56

Alto Neuroscience Interest Income Calculation

Interest Income is the interest earned on cash temporarily held in savings accounts, certificates of deposits, or other investments.

Interest Income for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $2.30 Mil.

Alto Neuroscience (Alto Neuroscience) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Alto Neuroscience Inc (NYSE:ANRO) » Definitions » Interest Income

Comparable Companies

Traded in Other Exchanges

N/A

Address

Website

Alto Neuroscience Inc is a clinical stage biopharmaceutical company with a mission to redefine psychiatry by leveraging individuals' neurobiology to develop personalized and highly effective treatment options. the company currently consists of five clinical-stage assets initially targeting major depressive disorder and schizophrenia populations as identified by independent brain-based biomarkers.

Alto Neuroscience (Alto Neuroscience) Headlines

From GuruFocus

Steven Cohen's Point72 Asset Management Buys New Stake in Alto Neuroscience Inc

By GuruFocus Research • 02-08-2024